Loading clinical trials...

Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients | Clinical Trials | Clareo Health

UNKNOWNPHASE3

Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients

Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)

NCT01709994•Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales

View on ClinicalTrials.gov

Summary

The objective of the study is to examine whether the use of low-dose aspirin (75-100 mg / day) reduces the risk of cardiovascular disease in patients with chronic kidney disease (stage 3 or 4).

Detailed Description

Hypothesis: The low-dose aspirin reduces cardiovascular risk in patients with chronic kidney disease without increasing the risk of bleeding

Eligibility

Age

45 - 79 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•sign informed consent
•males 45-79 years or females 55-79 years. -Stage 3 or 4 CKD (estimated GFR by MDRD abbreviated, between 15 and 60 ml / min/1.73 m2) -

Exclusion Criteria

•a previous cardiovascular event: cardiac arrhythmias, cardiac arrest, angina or acute myocardial infarction, stroke, carotid stenosis of more than 50%, peripheral vascular arteriopathy documented
•hospitalization for any cause in the last three months prior to inclusion in the study allergy of acetyl-salicylic acid
•coagulopathy from any cause
•thrombocytopenia \<150,000 platelets
•liver disease from any cause
•Infection by hepatitis B virus, hepatitis C or HIV
•immunosuppressive treatment within 12 weeks before inclusion in the study
•Major bleeding events including gastrointestinal bleeding and brain hemorrhage.
•hemoglobinopathies (eg sickle cell disease or thalassemia of any kind)
•active malignancy (except non-melanoma skin cancer). May be included in the study patients with malignant neoplasia who have remained disease-free for at least the previous 5 years.
+5 more criteria

Locations (1)

Hospital General Universitario Gregorio Marañon

Madrid, Madrid, Spain

Key Dates

Start Date

May 1, 2010

Primary Completion Date

May 1, 2015

Completion Date

May 1, 2015

Last Updated

October 18, 2012

Enrollment

ESTIMATED participants

Conditions

Chronic Kidney Disease Stage 4Chronic Kidney Disease Stage 3

Interventions

Aspirin

DRUG

Contacts

JOSE LUÑO, MD, PHD

CONTACT

0034915868319 jluno.hgugm@salud.madrid.org

Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

NCT06939816

Chronic Kidney Disease Stage 2Chronic Kidney Disease Stage 3+1 more

View study

RECRUITING

Prediction of Peripheral Neuropathy With Functional Testing

NCT06933108

Chronic Kidney Disease Stage 3 and 4Diabetes

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 18, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients

Inclusion Criteria

Exclusion Criteria

Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

Prediction of Peripheral Neuropathy With Functional Testing

Kidney Transplant Improvement Through New Exercise Training to Increase Capacity

Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment

Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease

Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease